Rising Star in Focal Therapy Award

The Rising Star in Focal Therapy 2021


The ‘Rising Star in Focal Therapy’ award was developed to acknowledge the brightest and hardest working indiviual who has dedicated a signficant amount of time and effort in helping change the field of focal therapy.  To be eligible for this award one must be within five years of graduating trainging and be a full time practicing physician and a member of the Focal Therapy Society.

Sponsored by

Abhinav Sidana

MD, MPH is an Associate Professor and Director of Urologic Oncology in the Division of Urology at the University of Cincinnati Medical Center.

He is spearheading the management of patients with urologic cancers at UC Medical Center with a focus on prostate and kidney cancers. He has established a Focal Therapy Program at the University of Cincinnati Medical Center that has become one of the leading centers in the country for prostate cancer focal therapy.

Dr. Sidana completed his medical education at All India Institute of Medical Sciences in New Delhi, India. After graduating medical school, he spent two years as a Postdoctoral research fellow at the Brady Urological Institute of Johns Hopkins University under the mentorship of Dr. Ronald Rodriguez. His research was focused on cancer immunotherapy for urologic cancers and his lab research was translated to a phase 1 clinical trial of ‘cryoimmunotherapy’ in metastatic cancer. Subsequently, he completed urology residency at the University of Cincinnati College of Medicine and a urologic oncology fellowship at National Institutes of Health. At NIH, under the mentorship of Dr Peter Pinto, Dr Sidana developed research interest in functional prostate imaging, image-guided and focal treatments for prostate cancer which he is pursuing currently.

Dr Sidana is also interested in clinical trials on novel treatments for urologic cancers and serve as the Genitourinary Clinical Trials Leader at University of Cincinnati Cancer Center. He is Principal Investigator on several industry and cooperative group oncology clinical trials and recently received funding for a novel investigator-initiated multi-institutional systemic therapy/focal therapy combination trial. He serves as the Vice-Chair of the Research Committee for the International Focal Therapy Society and leads an international multi-institutional prospective registry for patients undergoing ablative therapy for prostate cancer.

In addition to his role within the Focal Therapy Society, Dr. Sidana serves as the course director of Frontiers in Oncologic prostate Care and Ablative Local (FOCAL) therapy annual meeting which aims to provide both the theoretical and hands on training to the urologists interested in incorporating focal therapy and newer BPH ablative modalities as management options for their patients.